Evolution and governance of the biotechnology and pharmaceutical industry of China

被引:21
|
作者
Wang, Kai [2 ]
Hong, Jin [1 ]
Marinova, Dora [3 ]
Zhu, Liang [2 ]
机构
[1] Univ Sci & Technol China, Sch Management, Hefei 230026, Anhui, Peoples R China
[2] Univ Sci & Technol China, Sch Humanities & Social Sci, Hefei 230026, Anhui, Peoples R China
[3] Curtin Univ Technol, Curtin Univ Sustainabil Policy CUSP, Perth, WA 6845, Australia
基金
澳大利亚研究理事会; 中国国家自然科学基金;
关键词
Biotechnology and pharmaceutical industry; Evolution; Governance; Actor-Networks theory (ANT); INNOVATION; US;
D O I
10.1016/j.matcom.2008.09.001
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
The high-speed growth of China's biotechnology industry during the past 20 years presents an excellent opportunity to examine its overall evaluation and governance from the perspective of science and technology policies. Although China's biotechnology industry has achieved tremendous extension both in scale and structure, the strengths it has gained from achievements in research and development activities have been significantly weakened in relation to processes of commercialization. After examining the definition of China's biotechnology industry as well as its evolution, the authors of this paper employ Actor-Networks Theory as a basic theoretical framework to reveal how China's biotechnology industry develops in the form of evolving networks within the country's social context and to identify what kinds of relationships exist among the relevant factors. Our hope is to provide guiding insights for improving the governance of China's biotechnology industry both in policy and in management practices. Crown Copyright (C) 2008 Published by Elsevier B.V. on behalf of IMACS. All rights reserved.
引用
收藏
页码:2947 / 2956
页数:10
相关论文
共 50 条
  • [22] The future and the biotechnology industry - New trends in pharmaceutical development
    Dibner, MD
    [J]. BIOPHARM-THE APPLIED TECHNOLOGIES OF BIOPHARMACEUTICAL DEVELOPMENT, 2001, 14 (06): : 26 - +
  • [23] BIOTECHNOLOGY AND THE PHARMACEUTICAL-INDUSTRY - NEW CARDIOVASCULAR DRUGS
    DIBNER, MD
    TIMMERMANS, PBMWM
    [J]. HYPERTENSION, 1986, 8 (11) : 965 - 970
  • [24] Biotechnology in the production of pharmaceutical industry ingredients: Amino acids
    Stoimenova, Assena
    Ivanov, Kalin
    Obreshkova, Danka
    Saso, Luciano
    [J]. Biotechnology and Biotechnological Equipment, 2013, 27 (02): : 3620 - 3626
  • [25] Proteomics in the pharmaceutical and biotechnology industry: a look to the next decade
    Lill, Jennie R.
    Mathews, William R.
    Rose, Christopher M.
    Schirle, Markus
    [J]. EXPERT REVIEW OF PROTEOMICS, 2021, 18 (07) : 503 - 526
  • [26] Strengthening the Biological Weapons Convention and implications on the pharmaceutical and biotechnology industry
    Zabriskie, D
    [J]. CURRENT OPINION IN BIOTECHNOLOGY, 1998, 9 (03) : 312 - 318
  • [27] EMERGING TRENDS IN BIOTECHNOLOGY - A PERSPECTIVE FROM THE PHARMACEUTICAL-INDUSTRY
    SZKRYBALO, W
    [J]. PHARMACEUTICAL RESEARCH, 1987, 4 (05) : 361 - 363
  • [28] Can biotechnology lead the way toward a sustainable pharmaceutical industry?
    Etit, Deniz
    Meramo, Samir
    Ogmundarson, Olafur
    Jensen, Michael K.
    Sukumara, Sumesh
    [J]. CURRENT OPINION IN BIOTECHNOLOGY, 2024, 87
  • [29] Shift in interests towards biotechnology in Indian pharmaceutical industry: an analysis
    Visalakshi, S
    Prasad, A
    [J]. RESEARCH EVALUATION, 2001, 10 (03) : 173 - 183
  • [30] THE IMPACT OF BIOTECHNOLOGY AND MOLECULAR-BIOLOGY ON THE PHARMACEUTICAL-INDUSTRY
    HOBDEN, AN
    HARRIS, TJR
    [J]. PROCEEDINGS OF THE ROYAL SOCIETY OF EDINBURGH SECTION B-BIOLOGICAL SCIENCES, 1992, 99 : 37 - 45